India, July 9 -- Lupin Limited has announced the signing of a License and Supply Agreement with Zentiva, k.s., a leading pharmaceutical company based in the Czech Republic, for the commercialization of Lupin's biosimilar Certolizumab Pegol.
Under the terms of the agreement, Lupin will handle the development, manufacturing, and supply of the biosimilar across agreed territories. Zentiva will take charge of commercialization activities in Europe and CIS countries, leveraging its robust regulatory expertise and commercial infrastructure in the region. Lupin will independently manage commercialization in other markets, including the United States and Canada. The partnership excludes Australia, Japan, Brazil, the Philippines, and India.
As par...